A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome.

导出 OA

翻译打印收藏纠错

作者： David G,Sweet ^[1] ; Mark A,Turner ^[2] ; Zbyněk,Straňák ^[3] ; Richard,Plavka ^[4] ; Paul,Clarke ^[5] ; Ben J,Stenson ^[6] ; Dominique,Singer ^[7] ; Rangmar,Goelz ^[8] ; Laura,Fabbri ^[9] ; Guido,Varoli ^[9] ; Annalisa,Piccinno ^[9] ; Debora,Santoro ^[9] ; Christian P,Speer ^[10]

作者单位： Neonatal Unit, Royal Maternity Hospital, Belfast, Northern Ireland, UK. ^[1] Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, England, UK. ^[2] Department of Neonatology, Institute for the Care of Mother and Child, Prague, Czech Republic. ^[3] Division of Neonatology, General Faculty Hospital and 1st Faculty of Medicine, Prague, Czech Republic. ^[4] Neonatal Intensive Care Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK. ^[5] Neonatal Unit, Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, Edinburgh, Scotland, UK. ^[6] Division of Neonatology and Paediatric Intensive Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ^[7] Department of Neonatology, University Children's Hospital, Tuebingen, Germany. ^[8] Global Clinical Development, Chiesi Farmaceutici S.p.A, Parma, Italy. ^[9] University Children's Hospital, University of Würzburg, Würzburg, Germany. ^[10]

关键词 clinical trial cohort study respiratory distress syndrome safety surfactant